Tissue-based companion diagnostics: Development of ihc assays from an industry perspective
Methods in Pharmacology and Toxicology, ISSN: 1940-6053, Vol: 20, Page: 281-304
2015
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Book Chapter Description
In the last decade an increasing number of collaborations were established between pharma and diagnostic companies on the development of companion diagnostic assays to identify patients that will most likely respond to targeted therapies under development. This chapter focuses on the development of immunohistochemistry assays as companion diagnostics, which includes biomarker expression and specimen types, antibody selection and optimization, assay protocol development and optimization, assay verification and validation, and clinical validation. Past examples of companion diagnostic assay development, timeline coordination of drug-diagnostic co-development, and regulatory considerations are also briefly discussed.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84935825776&origin=inward; http://dx.doi.org/10.1007/7653_2014_26; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85026266967&origin=inward; https://link.springer.com/10.1007/7653_2014_26; https://dx.doi.org/10.1007/7653_2014_26; https://link.springer.com/protocol/10.1007/7653_2014_26
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know